Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AZD2693 in Healthy Participants
NCT05107336Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2021
- Primary completion
- Mar 2023
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AZD2693 in metabolic dysfunction-associated steatohepatitis (MASH) and Nonalcoholic steatohepatitis (NASH) (5 arms), sponsored by AstraZeneca. Primary endpoint: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) at Day 162. Started Nov 2021; status: completed.
02
Drugs
AZD2693
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05107336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05107336.